SLC5A2 and heart failure: These findings were further confirmed in a meta-analysis by Kaze et al., where the pooled effect size of SGLT2 inhibitors from data of the CVOTs and the renal outcome trials found that using an SGLT2 inhibitor lowered the risk of MACE by 17% (I2 = 33.8%, P = 0.183) and substantially lowered the risk of hospitalization for heart failure (HHF) by 38% (I2 = 0%, P = 0.844) [32].